Pulmonary Adenosquamous Carcinoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-11-08
Clinical Trial Update: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma [Phase 2]
Phase 2 trial evaluating almonertinib as first-line treatment for EGFR-positive pulmonary adenosquamous carcinoma or combined adenocarcinoma…